Supernus Pharmaceuticals (SUPN) Inventory (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Inventory data on file, last reported at $87.1 million in Q1 2026.

• Inventory for Q1 2026 came in at $87.1 million, up 76.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.1 million (up 76.16% YoY), and the FY2025 annual result was $82.4 million, up 51.74% from the prior year.
• Inventory rose to $87.1 million in Q1 2026 per SUPN's latest filing, from $82.4 million in the prior quarter.
• Over five years, Inventory peaked at $91.5 million in Q4 2022 and troughed at $44.0 million in Q2 2025.
• A 5-year average of $76.2 million and a median of $82.4 million in 2025 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2025: Inventory soared 76.79% in 2022, then plunged 35.41% in 2025.
• A 5-year view of Inventory shows it stood at $91.5 million in 2022, then declined by 15.44% to $77.4 million in 2023, then slipped by 29.86% to $54.3 million in 2024, then soared by 51.74% to $82.4 million in 2025, then gained by 5.68% to $87.1 million in 2026.
• Business Quant data shows SUPN's Inventory at $87.1 million in Q1 2026, $82.4 million in Q4 2025, and $79.4 million in Q3 2025.